Our observations support recent studies demonstrating that IL‐37 treatment restores normal T‐cell function (reduction in IL‐17 production) in the chronic inflammatory setting of allergic rhinitis (Li, Shen, et al., 2018). This evidence concerns the gene IL17A and allergic rhinitis.